Decheng Capital Management III (Cayman)’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,333,254	Closed	-$4.25M	–	26
2022 Q1	$4.25M	Buy	+1,333,254	New	+$3.83M	1.3%	15

Decheng Capital Management III (Cayman)'s CMPI Position: Q2 2022 in Review

Decheng Capital Management III (Cayman) sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 1,333,254 shares — an estimated $4.25M sold.

Decheng Capital Management III (Cayman) first reported a position in CMPI in Q1 2022 and held it in 1 quarter. The position peaked at $4.25M in Q1 2022. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Decheng Capital Management III (Cayman) reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Decheng Capital Management III (Cayman) sold 1,333,254 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $4.25M.
Decheng Capital Management III (Cayman) first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Decheng Capital Management III (Cayman)'s Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $4.25M in Q1 2022.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q2 2022, filed 1 Aug 2022.